Ann: Phase 2 trial shows significant improvements in Angelman, page-72

I posted this yesterday

….the market is totally focused on existing revenue streams (drugs on market) and if they may be slightly downgraded in the near term (which has an immaterial impact on future earnings) and are missing the far bigger pipeline opportunities (5-10x) that in each case open up markets that are multiples of their existing revenue streams. (Melissa Benson, Wilsons Advisory)

Today, Neuren announced the third successive successful Phase 2 result for NNZ-2591. However, in line with those comments yesterday, the market appeared to remain anally fixated on a slight downgrade in projected royalty revenue from DayBue.

To keep it simple, there were two headlines of key significance in the Angelman results presentation today

Results further strengthen confidence in potential of NNZ-2591 for multiple neurodevelopmental disorders, independent of origin of underlying genetics

Phase 2 trial results validating multi-indication platform

This is the main game and this should be the focus – today’s third successful result surely validates NNZ-2591 as a multi-indication platform, aka a “pipeline-in-a-drug”.